Best Contract Sales Organizations (CSOs) in Healthcare 2026: An Honest Comparison

A contract sales organization (CSO) is an outside firm that employs, trains, and manages sales reps who promote your product under contract. Pharma and device companies use CSOs to fill territories without hiring W2 reps. The largest players are IQVIA, Syneos Health, Amplity, and Eversana. Typical engagements start around 10 to 15 reps on 6 to 12 month contracts, at roughly $185,000 to $240,000 per rep per year. This guide compares the major CSOs on cost, contract terms, and rep quality, and shows when a contract talent marketplace covers the same territory faster and for less.

Key takeaways

• This article compares traditional CSOs (IQVIA, Syneos, Amplity, Eversana) — vendors that employ reps and run managed field programs.
• MDliaison is not a CSO. We are a marketplace: pre-vetted 1099 contractors, matched in 1–3 weeks, with you running the rep day-to-day.
• Choose a CSO for 15+ rep, fully managed programs; choose the marketplace model for 1–10+ reps, territory tests, and flexible coverage.

You're reading this because you have territories that need reps, and your internal team can't fill them fast enough. That's the reason anyone looks at CSOs.

So I'm going to skip the preamble and give you what you need: who the major players are, what they actually charge, where they deliver, and where they don't. Then I'll cover the alternative that's been quietly taking market share from traditional CSOs for the past three years.

What is a contract sales organization (CSO) in pharma?

A pharmaceutical contract sales organization is a company that fields sales teams on behalf of drug and device makers. The CSO employs the reps, runs payroll and compliance, and manages them day to day. Clients buy coverage rather than headcount. Core services include dedicated sales teams that work a single client's product, syndicated teams that promote several non-competing products, vacancy management to cover open territories, and launch support for new drugs. A CSO is not a CRO: contract research organizations run clinical trials, while contract sales organizations run commercial field teams. The model exists because building an in-house sales force is slow and carries fixed overhead that many companies, especially those with one product or a patent cliff approaching, cannot justify.

Contract sales in the medical industry spans three models buyers confuse: traditional CSOs (vendor-employed reps on managed programs), specialized recruiters (W2 placement fees), and contractor marketplaces (pre-vetted 1099 reps you run directly).

For pharma and medtech companies comparing options:

• CSO / contract sales organization — best at 15+ rep, multi-state programs with vendor-managed field management. See our CSO comparison.
• Marketplace — best for 1–10+ reps, territory tests, and flexible hours without placement fees. See contract sales teams on MDliaison.
• Recruiter — best when you want one permanent W2 hire and can wait 60–120 days. Compare costs on /pharmaceutical-sales-recruiters. For the full fee math, firm list, and when to skip the recruiter entirely, see what medical sales recruiters cost.

If you are still mapping models, start with the CSO comparison — then decide whether you need vendor-managed scale or fast contractor coverage.

How much does a contract sales organization cost?

Pharma CSOs typically charge between $185,000 and $240,000 per rep per year. The underlying cost of the rep, including salary, benefits, car allowance, and overhead, runs closer to $133,000, which means a 10-rep deployment generates roughly $520,000 to $1.07 million in gross margin for the CSO over a standard contract. Pricing is usually quoted as a monthly fee per rep with a 6 to 12 month minimum term. Contract reps hired through an hourly marketplace typically cost 20 to 35 percent less for equivalent experience, because there is no management layer priced into the rate. When you compare quotes, ask for the fully loaded per-rep number and the early termination terms, since both vary more than the headline rate.

Before we talk about specific companies, you need to understand the economics. Most CSOs won't publish their pricing, so let me give you a framework based on what I see in actual contracts.

A CSO hires a rep as a W2 employee. That rep might earn $87K base plus $25K in benefits, $9K in payroll taxes, and $12K in car and expenses. The CSO's actual cost per rep is roughly $133K.

The CSO charges you somewhere between $185K and $240K per rep annually, depending on therapeutic area, geography, and contract size. That $52K-$107K spread is recruiting, training, management overhead, and profit margin.

For a 10-rep deployment, you're paying $1.85M-$2.4M annually. The CSO's gross margin on that contract is somewhere around $520K-$1.07M.

That margin isn't evil. It pays for real services. But you should know what you're buying before you sign, because depending on your situation, you might be overpaying for services you don't need.

How big is the pharma CSO market?

The global pharmaceutical contract sales organization market is estimated at $11.6 billion in 2026 and is projected to reach $17.3 billion by 2031, a compound annual growth rate of about 8.3 percent, according to Mordor Intelligence. Grand View Research puts the market at $18.1 billion by 2030, growing at 8.8 percent annually. North America is the largest region, holding roughly 43 percent of global revenue. Three forces drive the growth: patent cliff exposure, with about 190 drugs facing $236 billion in revenue loss by 2030, pushing manufacturers toward variable commercial spend; a wave of mid-sized biotechs reaching commercialization without internal field infrastructure; and the shift toward specialty and biologics portfolios that need experienced, flexible sales coverage. The same forces are growing the contract talent marketplace segment, where companies hire individual reps directly instead of buying a managed team.

Who are the largest pharma contract sales organizations?

The largest pharma CSOs are IQVIA Contract Sales, Syneos Health, Amplity Health, and Eversana, with Inizio Engage also fielding major global teams. All of them operate on the managed-team model: they employ the reps and sell you coverage at scale. Below is what each is known for, their typical engagement shape, and what to watch for in their contracts.

IQVIA

IQVIA is the biggest. They came out of the Quintiles-IMS merger, and they have more data, more infrastructure, and more deployed reps than anyone else in the space.

Where IQVIA wins: scale deployments. If you need 40 reps across 12 states in 90 days, IQVIA can do it. Their recruiting pipeline is deep enough to handle that volume. Their training programs are templated and efficient. Their management structure is built for large engagements.

Where IQVIA struggles: small, specialized needs. If you need 3 experienced oncology reps in the Northeast, IQVIA's machinery is overkill. You'll pay the same overhead percentage whether you're deploying 3 reps or 30. And because IQVIA is managing thousands of reps across hundreds of engagements, the individual attention to your specific program can feel thin.

Typical contract: 12-month minimum, 15-rep minimum in some cases, with 60-90 day termination notice. Pricing on the higher end of the range I mentioned above.

Syneos Health

Syneos Health combines contract sales with clinical development services. That integration is their pitch: you can get your Phase III trial and your launch team from the same company.

In practice, most clients use one side or the other. But for companies that genuinely need both, particularly mid-size pharma launching their first or second product, the integration can reduce coordination overhead.

Syneos has invested heavily in specialty pharma, and their rep quality in therapeutic areas like oncology and rare disease is generally strong. They're pickier about which reps they deploy, which means slower ramp-up but better performance once the team is in place.

Typical contract: 12-month minimum, pricing comparable to IQVIA, with some flexibility on smaller engagements.

Amplity Health

Amplity Health (formerly Publicis Health Solutions) differentiates by wrapping sales reps in a broader commercial package: medical science liaisons, nurse educators, digital engagement, and market access support.

If your product requires significant physician education alongside the sales effort, Amplity's integrated model can work. You're not just putting a rep in the territory; you're putting a mini commercial team in the territory. For complex biologics or specialty products where the clinical conversation is as important as the commercial one, that can be worth the premium.

The premium is real, though. Amplity's pricing reflects the breadth of services. If you only need sales coverage and nothing else, you're paying for capabilities you won't use.

Eversana

Eversana takes integration further than anyone else. They'll handle your distribution, patient services, market access, and field sales under one contract. It's essentially outsourced commercialization.

For pre-commercial pharma companies launching their first product, Eversana solves a real problem: you don't have any commercial infrastructure, and building it from scratch takes 18-24 months. Eversana can deploy a functioning commercial operation in a fraction of that time.

The tradeoff is dependency. When one vendor handles your distribution, your patient support program, and your sales force, you're deeply embedded. Switching providers or bringing functions in-house later is a major undertaking. Companies that grow successfully often outgrow the Eversana model and face a painful transition to internal operations.

What percentage of CSO reps get replaced?

Industry-average CSO rep turnover runs 15 to 22 percent within the first six months of a deployment. Every replacement restarts territory relationships and typically costs one to two months of coverage momentum. A CSO that holds replacement under 10 percent is performing well, and that number is knowable in advance: ask any CSO you evaluate what percentage of deployed reps were replaced across their last three engagements, and whether replacement time counts against your contract. The replacement-rate question surfaces more about a CSO's rep quality than any capability deck.

There's a question that's hard to answer cleanly: do CSO reps perform as well as in-house reps?

The honest answer is it depends heavily on the therapeutic area, the CSO's recruiting standards, and how the engagement is managed. I've seen CSO teams that outperform in-house teams because the CSO recruited better talent for that specific situation. I've also seen CSO teams underperform because the reps were generalists assigned to a specialty role they weren't prepared for.

The structural issue is incentive alignment. A CSO is motivated to fill seats. They need utilization to generate revenue. That incentive can conflict with your need for the best possible rep in each territory. Good CSOs manage this tension through rigorous vetting. Mediocre CSOs fill seats and hope for the best.

One proxy metric I use: ask the CSO what percentage of deployed reps are replaced during the first six months of a contract. Industry average is somewhere around 15-22%. If a CSO tells you their number is under 10%, that's a good sign. If they won't share the number, draw your own conclusions.

CSO vs. marketplace: what is the difference?

The structural difference is who employs and manages the rep. A CSO sells you a managed team: their reps, their managers, their process, at team-scale minimums. A marketplace connects you directly with individual contract reps: you choose the person, pay hourly, and manage the work yourself, with coverage typically starting in 1 to 3 weeks. Neither is universally better. The comparison table below shows where each model wins.

Over the past few years, a different approach has been gaining traction. Instead of contracting with a CSO that recruits, employs, and manages reps on your behalf, companies are working directly with pre-vetted independent sales professionals through talent marketplaces.

The economics are different. No CSO markup. No management overhead you're subsidizing. No 12-month minimums.

A contract rep through a marketplace typically costs 20-35% less than the same caliber rep through a traditional CSO, because you're not paying for the CSO's recruiting team, management layer, office infrastructure, and profit margin. You're paying the rep for their expertise and a platform fee for the matching service.

The reps in these networks tend to be experienced professionals who have deliberately chosen independent work. They're not between jobs. They're not hoping to get hired full-time somewhere. They're people with 8, 12, 15 years of experience who prefer the flexibility and variety of contract engagements. That self-selection tends to produce a higher floor of quality than a CSO that's recruiting from the general market.

The limitation is management. A traditional CSO provides a field management layer. Your regional manager at the CSO supervises the reps, handles performance issues, and reports to you. In the marketplace model, you're managing the reps more directly, or using your existing field management structure. If you already have regional managers and just need reps to manage, this isn't a problem. If you need someone else to handle everything, the CSO model still has its place.

MDliaison is a marketplace, not a CSO. We match hiring companies with pre-vetted 1099 medical sales professionals across device, pharma, physician liaison, and health-tech — typically in 1–3 weeks, with no placement fee and no 10-rep minimum. You set priorities and manage the rep; we handle vetting, matching, time tracking, and billing.

CSO vs. marketplace at a glance

How do you evaluate a contract sales organization?

When evaluating CSOs, don't just look at their size. Ask these critical questions:

1. What is your exact turnover rate for deployed reps? Not your corporate average—your field average.
2. Who owns the relationships if we terminate the contract? (The answer should be you).
3. What are the specific exit conditions?

In 2024, a specialty pharma company signed a CSO contract for a cardiology product launch. The agreement covered 38 territories across the Southeast. Eight months in, they were locked into a 14-month minimum commitment with reps who had averaged fewer than 60 details per week and couldn't name the top five prescribers in their territories from memory.

The CSO had disclosed everything. It was in the contract. But the contract was 51 pages, and nobody had read page 34, which is where the performance remediation process was buried — a process that required six weeks of documented underperformance before any corrective action could trigger.

I see versions of this situation more than I should. And the companies involved aren't naive. They're experienced pharma commercial teams who moved too fast during a launch timeline and treated CSO selection the way you'd treat an approved vendor procurement process, not the way you'd treat hiring the people responsible for your drug's first-year market share.

Here's the evaluation framework I'd use if I were on the other side of that table.

The six questions that surface the real picture

Most CSO sales conversations are competent. They'll show you rep credentials, territory coverage maps, therapeutic area experience. That information is useful but insufficient. The questions that actually differentiate are the ones the CSO isn't expecting.

Question 1: What percentage of your current rep roster worked in branded pharmaceutical sales before joining your organization?

A high proportion of experienced branded reps signals a different network than a CSO that primarily recruits from medical device, specialty generics, or hospital distribution backgrounds. The distinction matters because branded pharma relationships — the ones built around pulling prescribers toward formulary-favored products — are hard to transfer from other sales contexts. Ask for the actual number, not a range.

Question 2: What's your average rep tenure, and what's your 12-month turnover rate?

High turnover in a CSO's own workforce is a problem that compounds directly into your launch. A rep who's been with the organization for four months has weaker internal support, weaker training compliance, and weaker accountability than a rep who's been there for three years. Turnover rates above 25% annually in a field sales organization are worth probing hard. Above 35%, I'd treat it as a disqualifying signal.

Question 3: Walk me through a launch where you underperformed against projections. What happened, and what changed?

Every CSO has one. The good ones can tell you specifically what went wrong — was it a territory size miscalculation, a therapeutic area the reps weren't ready for, a prescriber access problem they didn't anticipate? Vague answers here usually mean they either don't track performance at the rep level in enough detail to diagnose problems, or they don't want to tell you what actually happened. Neither is a good sign.

Question 4: What are the specific conditions under which we can exit the contract without penalty?

Not "what's your exit clause" — that question gets you a recitation of the contract terms. "What are the specific conditions" forces them to explain what the remediation process looks like in practice, how long it takes, and what your realistic options are if performance is poor but doesn't technically breach the SLA threshold. If they can't answer this without pulling up the contract, that's information.

Question 5: How do you handle rep replacement when a specific territory rep isn't performing?

Some CSOs treat replacement requests as a client right, others treat them as a negotiation. The difference matters enormously if you're six months into a launch with a rep who isn't building relationships in a key hospital system. Get the specific process in writing, including timelines. "We'll address it promptly" is not a process.

Question 6: Can you provide three client references in our therapeutic category who launched in the past 18 months?

Not clients in general. Not clients with similar product types. Clients who launched branded products in your specific therapeutic area, recently. Then call them. Don't email. Ask what they'd do differently and listen for the hesitations.

Red flags in the response

Beyond the answers themselves, watch how the CSO responds to these questions.

A CSO that answers question four (exit conditions) fluently and without hesitation has been asked it many times and is comfortable with their terms. A CSO that pivots to their client retention rate has just told you their exit clause is not their competitive advantage.

A CSO that reframes question two (turnover) as a strength ("we actively manage out underperformers") without providing the actual number is not going to provide the actual number. Push.

A CSO that can't name specific prescriber-facing challenges from a past launch in your category — not generically, but specifically — has not done a launch in your category recently enough for the experience to be current.

Contract terms worth fighting for

Most CSO contracts are written to protect the CSO. That's not cynical, it's just accurate. The negotiation points that matter most:

Performance-based milestones tied to exit rights. Define specific, measurable metrics — detail frequency, prescriber reach, target decile penetration — with a 90-day review window. If the metrics aren't met, you want a no-penalty exit or a rep replacement option, not a remediation period that lasts longer than a quarter.

Territory-level reporting. Aggregate performance reporting is nearly useless for identifying where problems are. You need individual territory metrics — by rep, by prescriber target, by call frequency — at a minimum monthly cadence. This should be contractual, not a verbal commitment.

Named rep approval rights. Before a rep is deployed in your territory, you should have the right to review their credentials and pharma experience and decline if they don't meet your standards. Some CSOs resist this. The ones that resist it hardest are usually the ones with the weakest available roster in your geography.

Transition assistance language. If the relationship ends — for any reason — you want a 60-day transition period during which the CSO cooperates with handing off accounts, relationship documentation, and call notes. Without this language, you can lose months of account intelligence.

The faster alternative

For companies that want dedicated reps without CSO contract complexity, direct contractor placement is worth the conversation. An experienced pharmaceutical 1099 contractor working a defined territory under a direct agreement gives you the rep dedication of a W-2 hire with faster placement timelines and without 18-month lock-in provisions.

The tradeoff is that you're managing the relationship more directly — there's no CSO infrastructure handling training and compliance oversight. For companies with an existing commercial infrastructure who just need the headcount, this is usually the better arrangement.

For companies launching from scratch without commercial ops in place, a CSO relationship that includes those support functions can make sense — provided you've asked the right questions first.

What are typical CSO contract minimums?

Most pharma CSOs require a minimum team of around 10 to 15 reps and a contract term of 6 to 12 months. Below that scale, CSOs generally decline the engagement or price it high enough that the economics stop working, because their model depends on spreading management and recruiting overhead across a team. That minimum is the main reason smaller companies and single-territory needs fall outside the CSO model. If you need anywhere from one to ten or more reps, a test territory, or coverage inside three weeks, the practical alternatives are direct hire, which is slow, or a contract talent marketplace such as MDliaison, where you select individual pre-vetted reps, pay hourly, and run the rep day to day yourself.

Making the Decision

Here's a quick rubric.

Choose a traditional CSO if you need 15+ reps deployed nationally, you want a fully managed solution with minimal internal oversight, and your budget accommodates the markup. IQVIA and Syneos are the strongest options at scale.

Choose a specialized CSO like Amplity if your product requires integrated medical education and sales support, particularly for complex specialty products.

Choose Eversana if you're a pre-commercial company that needs an entire commercial infrastructure built from scratch and you understand the dependency tradeoff.

Choose a marketplace model if you need fewer than 15 reps, you want experienced specialists rather than generalist reps, your needs are variable or shorter-term, you have existing field management, or the CSO markup doesn't make economic sense for your situation.

Do nothing if you're not sure what you need. Seriously. A bad outsourcing decision is expensive to unwind. Take the time to define the scope, the timeline, and the budget before you engage anyone.

The worst outcome isn't choosing the wrong model. It's leaving territories empty while you deliberate. Whatever you decide, decide quickly. Revenue doesn't wait.

For a breakdown of what companies actually pay, see CSO pricing models in 2026.

Quick answers

Does IQVIA do contract sales?

Yes. IQVIA Contract Sales is one of the largest CSO operations globally, offering dedicated and syndicated field teams, HCP engagement, and vacancy management, backed by IQVIA's data business. Engagements follow the standard CSO shape: managed teams, team-scale minimums, and multi-month contract terms. See the IQVIA section above for evaluation notes.

What is the difference between a CSO and a CRO?

A CRO (contract research organization) runs clinical development: trials, regulatory work, and data management. A CSO (contract sales organization) runs commercialization: field sales teams, HCP engagement, and territory coverage. Some large vendors, like IQVIA, operate both under one roof, but the services, contracts, and buyers are different.

Can a small biotech use a CSO?

Usually not economically. CSO minimums of roughly 10 to 15 reps and 6 to 12 month terms price out most pre-commercial and single-product biotechs. Smaller teams typically either hire one experienced contract rep through a marketplace, hire a fractional sales leader, or delay field coverage until launch scale justifies a managed team.